Research Analysts Offer Predictions for WST Q3 Earnings

West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) - Investment analysts at William Blair lowered their Q3 2025 earnings per share (EPS) estimates for West Pharmaceutical Services in a note issued to investors on Friday, April 25th. William Blair analyst M. Larew now expects that the medical instruments supplier will post earnings per share of $1.60 for the quarter, down from their prior estimate of $1.68. The consensus estimate for West Pharmaceutical Services' current full-year earnings is $6.62 per share. William Blair also issued estimates for West Pharmaceutical Services' Q4 2025 earnings at $1.69 EPS, Q1 2026 earnings at $1.59 EPS, Q2 2026 earnings at $1.74 EPS, Q3 2026 earnings at $1.83 EPS and Q4 2026 earnings at $1.93 EPS.

Other equities analysts have also recently issued research reports about the stock. Stephens raised shares of West Pharmaceutical Services to a "strong-buy" rating in a research note on Monday, April 21st. Deutsche Bank Aktiengesellschaft raised shares of West Pharmaceutical Services from a "hold" rating to a "buy" rating and set a $250.00 target price on the stock in a research note on Friday, February 14th. Citigroup began coverage on shares of West Pharmaceutical Services in a report on Wednesday, January 8th. They set a "buy" rating and a $400.00 target price for the company. StockNews.com lowered shares of West Pharmaceutical Services from a "buy" rating to a "hold" rating in a report on Thursday, February 27th. Finally, KeyCorp cut their target price on shares of West Pharmaceutical Services from $470.00 to $325.00 and set an "overweight" rating for the company in a research report on Friday, February 14th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $332.50.

West Pharmaceutical Services Stock Performance

NYSE WST traded down $1.17 during trading hours on Monday, reaching $210.12. 247,111 shares of the company were exchanged, compared to its average volume of 999,110. The stock has a market capitalization of $15.10 billion, a P/E ratio of 31.40, a P/E/G ratio of 6.74 and a beta of 1.22. The company has a quick ratio of 2.23, a current ratio of 2.79 and a debt-to-equity ratio of 0.08. The business's 50 day simple moving average is $218.37 and its 200-day simple moving average is $282.21. West Pharmaceutical Services has a 1 year low of $187.43 and a 1 year high of $372.79.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The medical instruments supplier reported $1.45 EPS for the quarter, beating the consensus estimate of $1.22 by $0.23. West Pharmaceutical Services had a return on equity of 18.60% and a net margin of 17.03%. The firm had revenue of $698.00 million during the quarter, compared to the consensus estimate of $685.24 million. During the same quarter in the previous year, the company posted $1.56 earnings per share. The company's quarterly revenue was up .4% on a year-over-year basis.

West Pharmaceutical Services Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, August 6th. Shareholders of record on Wednesday, July 30th will be issued a $0.21 dividend. This represents a $0.84 annualized dividend and a dividend yield of 0.40%. The ex-dividend date of this dividend is Wednesday, July 30th. West Pharmaceutical Services's dividend payout ratio is 13.19%.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Quadrant Capital Group LLC raised its position in shares of West Pharmaceutical Services by 5.4% in the 4th quarter. Quadrant Capital Group LLC now owns 626 shares of the medical instruments supplier's stock worth $205,000 after acquiring an additional 32 shares in the last quarter. Baron Wealth Management LLC increased its position in West Pharmaceutical Services by 1.9% during the 4th quarter. Baron Wealth Management LLC now owns 1,926 shares of the medical instruments supplier's stock valued at $631,000 after buying an additional 35 shares in the last quarter. Exchange Traded Concepts LLC increased its position in West Pharmaceutical Services by 18.9% during the 4th quarter. Exchange Traded Concepts LLC now owns 239 shares of the medical instruments supplier's stock valued at $78,000 after buying an additional 38 shares in the last quarter. Lake Street Advisors Group LLC increased its position in West Pharmaceutical Services by 5.8% during the 4th quarter. Lake Street Advisors Group LLC now owns 711 shares of the medical instruments supplier's stock valued at $233,000 after buying an additional 39 shares in the last quarter. Finally, Cornerstone Planning Group LLC increased its holdings in shares of West Pharmaceutical Services by 57.1% in the fourth quarter. Cornerstone Planning Group LLC now owns 110 shares of the medical instruments supplier's stock valued at $38,000 after purchasing an additional 40 shares during the period. 93.90% of the stock is owned by institutional investors.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.